No Data
No Data
People's Tongtai (600829.SH): Accelerating the layout of DTP pharmacies
Gelonghui, May 15, 丨 People's Tongtai (600829.SH) said at the performance briefing that with the advancement of medical reform policies, the reduction and concentration of distribution links has further increased competitive pressure on the industry. At the same time, major Internet giants, pharmaceutical manufacturers, and third-party logistics companies are all actively expanding drug distribution business and entering the pharmaceutical sales and logistics sector, and market competitive pressure is increasing. The company will pay close attention to national policy trends, adjust the market strategy and variety structure in a timely manner according to market changes, focus on regional target markets, and continuously improve endogenous profitability. The company will keep up with the development trend of Internet+ healthcare.
People's Tongtai (600829.SH): Net profit of 78.33 million yuan in the first quarter increased 9.12% year-on-year
On April 19, Ge Longhui (600829.SH) released its first quarter report. Operating revenue was 2,598 billion yuan, down 2.09% year on year, net profit of 78.33 million yuan, up 9.12% year on year, after deducting non-net profit of 77.135 million yuan, up 8.80% year on year, with basic earnings per share of 0.1,351 yuan.
HPGC Renmintongtai Pharmaceutical Corporation's (SHSE:600829) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
It is hard to get excited after looking at HPGC Renmintongtai Pharmaceutical's (SHSE:600829) recent performance, when its stock has declined 24% over the past three months. However, stock prices are
People's Tongtai (600829.SH): Net profit increased 10.47% year-on-year in 2023, and plans to distribute 10 1.44 yuan
On March 27, Ge Longhui (600829.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 10.39 billion yuan, an increase of 7.77%; net profit attributable to shareholders of listed companies of 292 million yuan, an increase of 10.47% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 287 million yuan, an increase of 10.02% year on year; and basic earnings per share. The 2023 profit distribution plan is: The company plans to distribute a cash dividend of 1.44 yuan (tax included) for every 10 shares to all shareholders.
HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
The HPGC Renmintongtai Pharmaceutical Corporation (SHSE:600829) share price has fared very poorly over the last month, falling by a substantial 26%. Longer-term shareholders would now have taken a
Is HPGC Renmintongtai Pharmaceutical (SHSE:600829) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
No Data